Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab biosimilar, JY-026, JY026 |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Plaque psoriasis | Phase 1 | China | 30 Jan 2022 | |
| Ankylosing Spondylitis | Phase 1 | China | 05 Feb 2020 | |
| Rheumatoid Arthritis | Phase 1 | China | 05 Feb 2020 | |
| Crohn Disease | IND Application | China | 08 May 2015 | |
| Juvenile Idiopathic Arthritis | IND Application | China | 08 May 2015 |






